Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
J Glaucoma. 2011 Oct;20(8):523-7. doi: 10.1097/IJG.0b013e3181f46337.
To evaluate the efficacy and safety of endoscopic cyclophotocoagulation (ECP) in the treatment of uncontrolled glaucoma with a prior aqueous tube shunt.
A prospective, nonrandomized, interventional clinical trial with up to 2 years of follow up included 25 eyes of 25 consecutive glaucoma patients with a previous tube shunt and uncontrolled intraocular pressure (IOP) despite medical therapy. Patients had IOP greater than 21 mm Hg on maximal medications or IOP ≤21 mm Hg but intolerant to medications or using an oral carbonic anhydrase inhibitor. Application of ECP over 360 degrees was performed and subjects were followed for 6 months minimum. Main outcome measures were mean reduction in IOP and medications at 12 months. Success was defined as reduction in IOP of 3 mm Hg and discontinuation of nontolerated glaucoma medications. A failure was defined as continued uncontrolled IOP, vision loss to no light perception, or additional medications or glaucoma surgery required.
At 12 months, the mean IOP dropped from 24.02 to 15.36 mm Hg. The mean of the differences was -7.77 mm Hg (-30.8%). The mean number of medications was 3.2 before laser and 1.5 at 12 months (P<0.001). The success rate at 12 months (n=18) was 88% and remained at that level until the end of the follow-up period of 2 years (n=11, P<0.00005). There were no serious complications.
ECP seems to be a safe and effective treatment in patients with uncontrolled IOP with a prior aqueous tube shunt, and is a reasonable option in this group of refractory glaucoma patients.
评估经巩膜睫状体光凝术(ECP)治疗既往存在房水引流管植入且眼压控制不佳的青光眼的疗效和安全性。
前瞻性、非随机、干预性临床试验,随访时间最长 2 年,纳入 25 例 25 只眼的青光眼患者,这些患者既往存在房水引流管植入,且尽管接受了药物治疗,眼压仍控制不佳。患者的最大药物治疗眼压>21mmHg,或眼压≤21mmHg,但不能耐受药物治疗或正在使用口服碳酸酐酶抑制剂。对巩膜进行 360 度 ECP 治疗,至少随访 6 个月。主要观察指标为治疗 12 个月时眼压和药物使用量的平均下降情况。成功定义为眼压降低 3mmHg 且停止使用不耐受的青光眼药物;失败定义为眼压持续不受控制、视力丧失无光感、需要额外药物或青光眼手术。
治疗 12 个月时,平均眼压从 24.02mmHg 降至 15.36mmHg,差值的平均值为-7.77mmHg(-30.8%)。治疗前平均用药数为 3.2 种,治疗 12 个月时为 1.5 种(P<0.001)。治疗 12 个月时的成功率(n=18)为 88%,在 2 年的随访期末仍保持这一水平(n=11,P<0.00005)。无严重并发症发生。
对于既往存在房水引流管植入且眼压控制不佳的患者,ECP 似乎是一种安全有效的治疗方法,是这组难治性青光眼患者的合理选择。